ClinicalTrials.gg
CompletedNCT02546323Updated Dec 11, 2019Results posted

A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis

A Phase 3 interventional study of Rosuvastatin and Placebo in Atherosclerosis, sponsored by AstraZeneca. Completed at 24 sites in China. Open to participants aged 45 Years to 69 Years. Per ClinicalTrials.gov, last updated 2019-12-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
543
Allocation
Randomized
Ages
45 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing rosuvastatin in Atherosclerosis — 1 open to participants now, 2 under way, 1 of them phase 3. rosuvastatin · Atherosclerosis.

Enrollment
3rd of 24
543 · median 77
Started
2015
with 2 others
Phase 3
6 of 25
1 open now
Registered
18th of 25
by date
Lead sponsor
5 of 25
AstraZeneca

Among the 25 studies testing rosuvastatin in Atherosclerosis, this one is the 3rd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 18th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 225 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

1 of the 25 studies testing rosuvastatin in Atherosclerosis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Atherosclerosis studies recruiting now, 84 (52%) set no upper age limit and 33 (20%) stop at 75 or younger; 16 take children under 18; 33 take healthy volunteers.

This study: 45 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing rosuvastatin in Atherosclerosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of of rosuvastatin 20 mg compared to placebo for treating Chinese patients with subclinical atherosclerosis.

Read the detailed description

This study is a randomized, double-blind, placebo-controlled, multicenter parallel group study assessing the effects of rosuvastatin 20 mg treatment for 104 weeks on the change in intimamedia thickness (IMT) of the common carotid artery (CCA), carotid bulb, and internal carotid artery (ICA) in adult Chinese subjects with subclinical atherosclerosis.

03

Conditions studied

  • Atherosclerosis

Browse trials for

Keywords

  • Rosuvastatin 20 mg treatment, Carotid Intima-Media Thickness, Chinese subjects, Subclinical atherosclerosis
04

Who can participate

Ages eligible
45 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study-specific procedures
  • Male aged ≥45 and \<70 years or female aged ≥55 and \<70 years
  • Subjects with only hypertension (as defined blood pressure ≥140/90 mmHg or on antihypertensive treatment) and age as CVD risk factors and subjects without hypertension who have 3 or more other risk factors (including age) must have "Fasting LDL C of ≥120 mg/dL (3.1 mmol/L) and \<160 mg/dL (4.1mmol/L)"; Subjects without hypertension who have fewer than 3 other risk factors (including age) must have "Fasting LDL-C of ≥120 mg/dL (3.1 mmol/L) and \<190 mg/dL (4.9 mmol/L)"
  • Triglycerides \<500 mg/dL (5.65 mmol/L) at Visit 1
  • HDL-C levels ≤60 mg/dL (1.6 mmol/L) at Visit 1
  • Maximum IMT ≥1.2 mm and \<3.5 mm at any location in the carotid ultrasound scans conducted at both Visit 2 and Visit 3
  • Willing to follow all study procedures including study visits, fasting blood draws, and compliance with study treatment regimen

Exclusion criteria

Exclusion Criteria:

  • Use of pharmacologic lipid-lowering medications (eg, statins, fibrate derivatives,bile acid binding resins, niacin, or its analogues at doses >400 mg or prescribed Chinese traditional drugs), including cholesterol-absorption inhibitors (CAIs), and CAI/statin combination, within 12 months prior to Visit 1
  • Current or recent (within 2 weeks of Visit 1) use of supplements known to alter lipid metabolism (eg, soluble fibers [including >2 teaspoons Metamucil® or psyllium-containing supplement per day] or other dietary fiber supplements, marine oils, sterol/stanol products, or other supplement determined at the discretion of the investigator)
  • History of reactions to other HMG-CoA reductase inhibitors
  • Pregnant women, women who are breast-feeding, and women of who are not using chemical or mechanical or who have a positive serum pregnancy test
  • Clinical evidence of coronary artery disease (CAD) or any other atherosclerotic disease such as angina, MI, , symptomatic CAD, cerebrovascular accident, percutaneous coronary intervention, coronary artery bypass graft, peripheral arterial disease, abdominal aortic aneurysm
  • History of cancer (other than basal cell carcinoma) in the past 2 years
  • Uncontrolled hypertension defined as either a mean resting diastolic blood pressure of ≥110 mmHg or a resting systolic blood pressure of ≥180 mmHg recorded at any time during the screening period
  • History of diabetes mellitus or current diabetes mellitus
  • Uncontrolled hypothyroidism defined as a thyroid stimulating hormone (TSH) >1.5 times the (ULN) at Visit 1 or subjects whose thyroid replacement therapy was initiated within the last 3 months
  • History of heterozygous or homozygous familial hypercholesterolemia or known hyperlipoproteinemia Types I, III, IV, or V (familial dysbetalipoproteinemia)
  • Use of the disallowed concomitant medications within 12 months prior to Visit 1
  • History of alcohol and/or drug abuse within the past 5 years
  • Active liver disease or hepatic dysfunction as defined by elevations of ≥1.5 x ULN at Visit 1 in any of the following liver function tests: , AST or
  • Serum creatine kinase (CK) >3 x ULN at Visit 1
  • Serum creatinine >2.0 mg/dL (177 mmol/L) recorded during the screening period
  • Participation in another drug study, and having ingested investigational drug ≤4 weeks before enrollment in the screening period
  • Previous randomization in the present study
  • History of a significant medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
543 participants (actual)

Study arms

  • Experimental
    Rosuvastatin

    20 mg tablets, Daily oral dose

    Drug: Rosuvastatin

  • Placebo comparator
    Placebo

    Matching placebo tablets

    Drug: Placebo

Interventions

  • 20mg tablets, orally once daily for the duration of the 104-week treatment period

    Also known as: Crestor

  • DrugPlacebo

    Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period

    CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

    Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).

Secondary outcomes

  1. Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA

    CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

    Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).

  2. Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb

    CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

    Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).

  3. Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA

    CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

    Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).

  4. Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA

    CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

    Time frame: From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).

  5. Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)

    The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol \[LDL-C\], total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I \[ApoA-I\], apolipoprotein B \[ApoB\] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.

    Time frame: From baseline (Week 0) to end-of-study (Week 104).

  6. Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average

    The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.

    Time frame: From baseline (Week 0) to end-of-study (Week 104).

07

Results

Posted Dec 11, 2019

Participant flow

Chinese patients with subclinical atherosclerosis and a 10-year ischemic cardiovascular disease (ICVD) risk of less than 10% (as assessed by the 2007 China Adult Dyslipidema Management Guidelines) were enrolled at 25 sites in China between 17 September 2015 and 29 January 2019.

Participant flow — Overall Study
MilestoneRosuvastatin 20 mgPlacebo
Started272271
Received treatment272268
Completed212205
Not completed6066
Withdrew: Withdrawal by subject3633
Withdrew: Eligibility criteria not fulfilled01
Withdrew: Adverse event1711
Withdrew: Patient specific reasons12
Withdrew: Lost to follow-up23
Withdrew: Non-compliance with study drug22
Withdrew: Met withdrawal criteria214

Outcome measures

PrimaryAnnualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period

CIMT measurements were made from ultrasound images of the common carotid artery (CCA), carotid bulb and internal carotid artery (ICA). The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. Twelve carotid artery sites were scanned at each visit and the 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for a specific segment. The annualized rate of change in the MeanMax CIMT measurements from each of the 12 sites, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

Time frame:
From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Reported as:
Mean · mm/year
Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period
mm/yearRosuvastatin 20 mgPlacebo
Annualized Rate of Change in Mean of the Maximum (MeanMax) CIMT Measurements From Each of the 12 Carotid Artery Sites Based on All Scans Performed During the 104-Week Study Period0.0038 ± 0.003120.0142 ± 0.00317
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · Multi-level mixed effects model · p = 0.020 (Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.) · Estimated mean difference: -0.0103 · 95% CI -0.0191 to -0.0016Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.
SecondaryAnnualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA

CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

Time frame:
From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Reported as:
Mean · mm/year
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA
mm/yearRosuvastatin 20 mgPlacebo
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left CCA-0.0031 ± 0.003100.0079 ± 0.00315
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · Multi-level mixed effects model · p = 0.013 (Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.) · Estimated mean difference: -0.0110 · 95% CI -0.0197 to -0.0024Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.
SecondaryAnnualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb

CIMT measurements were made from ultrasound images of the near and far walls of the right and left carotid bulb. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level linear mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

Time frame:
From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Reported as:
Mean · mm/year
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb
mm/yearRosuvastatin 20 mgPlacebo
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left Carotid Bulb0.0067 ± 0.006340.0228 ± 0.00643
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · Multi-level mixed effects model · p = 0.073 (Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.) · Estimated mean difference: -0.0162 · 95% CI -0.0339 to 0.0015Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.
SecondaryAnnualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA

CIMT measurements were made from ultrasound images of the near and far walls of the right and left ICA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the maximum of the CIMT for this segment. The annualized rate of change in the MeanMax CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

Time frame:
From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Reported as:
Mean · mm/year
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA
mm/yearRosuvastatin 20 mgPlacebo
Annualized Rate of Change in the MeanMax CIMT of the Near and Far Walls of the Right and Left ICA0.0077 ± 0.005020.0120 ± 0.00511
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · Multi-level mixed effects model · p = 0.547 (Statistical significance of the MeanMax CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.) · Estimated mean difference: -0.0043 · 95% CI -0.0183 to 0.0097Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients.
SecondaryAnnualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA

CIMT measurements were made from ultrasound images of the near and far walls of the right and left CCA. The thickness of the intima and media was determined as the distance from the interface between the vessel lumen and the intima, to the interface between the media and the adventitia. The 3 images recorded at the 3 interrogation angles were measured to determine the mean of the CIMT for this segment. The annualized rate of change in the MeanMean CIMT measurements, based on all scans performed during the study, was determined using a multi-level mixed effects regression model that estimated mean annualized rate of change (mm/year) over the 104-week study period. The model fitted regression lines to profiles of CIMT values consisting of 2 pre-randomization values, 3 values from visits during the treatment period, and 2 end-of-study visits.

Time frame:
From baseline (pre-randomization Week -2 and Week -4) to end-of-study (Week 104).
Reported as:
Mean · mm/year
Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA
mm/yearRosuvastatin 20 mgPlacebo
Annualized Rate of Change in the Mean of the Mean (MeanMean) CIMT of the Near and Far Walls of the Right and Left CCA-0.0011 ± 0.001910.0075 ± 0.00194
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · Multi-level mixed effects model · p = 0.002 (Statistical significance of the MeanMean CIMT annualized rate of change between rosuvastatin 20 mg and placebo was evaluated using time-by-treatment interaction term in the model.) · Estimated mean difference: -0.0086 · 95% CI -0.0139 to -0.0032Randomized treatment group, time, time-by-treatment interaction, ICVD risk stratification, carotid artery site, center, age, sex, and scan reader were fixed effects. Random effects were the intercept and slope for individual patients
SecondaryPercent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)

The percent change from baseline at final visit for lipid and lipoprotein measurements (low-density lipoprotein cholesterol \[LDL-C\], total cholesterol, high-density lipoprotein cholesterol \[HDL-C\], triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) and apolipoprotein measurements (apolipoprotein A-I \[ApoA-I\], apolipoprotein B \[ApoB\] and ApoB/ApoA-I ratio) was determined by analysis of covariance (ANCOVA) with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0) to the final visit at Week 104, any missing observations were imputed by LOCF.

Time frame:
From baseline (Week 0) to end-of-study (Week 104).
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lipid, Lipoprotein and Apolipoprotein Values at Final Visit: Last Observation Carried Forward (LOCF)
Percent changeRosuvastatin 20 mgPlacebo
LDL-C-26.47 ± 1.7008.99 ± 1.727
Total Cholesterol-20.56 ± 1.0101.29 ± 1.026
HDL-C5.47 ± 0.9440.48 ± 0.959
Triglycerides-7.26 ± 2.57512.38 ± 2.616
Non-HDL-C-27.67 ± 1.3441.82 ± 1.365
Non-HDL-C/HDL-C-28.52 ± 1.6373.23 ± 1.663
ApoB-24.20 ± 1.3071.91 ± 1.295
ApoA-I3.16 ± 0.7840.96 ± 0.777
ApoB/ApoA-I-25.14 ± 1.4501.63 ± 1.436
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -35.46 · 95% CI -40.23 to -30.70Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -21.85 · 95% CI -24.68 to -19.02Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 5.0 · 95% CI 2.35 to 7.64Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -19.65 · 95% CI -26.86 to -12.44Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -29.49 · 95% CI -33.25 to -25.72Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -31.75 · 95% CI -36.33 to -27.16Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -26.12 · 95% CI -29.73 to -22.50Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = 0.047 · Least squares mean difference: 2.19 · 95% CI 0.02 to 4.36Treatment as a fixed effect and baseline value as a covariate
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -26.77 · 95% CI -30.78 to -22.76Treatment as a fixed effect and baseline value as a covariate.
SecondaryPercent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average

The percent change from baseline at final visit for lipid and lipoprotein measurements (LDL-C, total cholesterol, HDL-C, triglycerides, non-HDL-C, non-HDL-C/HDL-C ratio) was determined by ANCOVA with treatment as a fixed effect and baseline value as a covariate. In the evaluation of change from baseline (Week 0), the time-weighted average value was calculated as the value multiplied by the number of days since the last assessment, summed for all observations, and divided by the sum of days between all visits.

Time frame:
From baseline (Week 0) to end-of-study (Week 104).
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in Lipid and Lipoprotein Values at Final Visit: Time Weighted Average
Percent changeRosuvastatin 20 mgPlacebo
LDL-C-34.89 ± 1.2754.62 ± 1.295
Total Cholesterol-23.98 ± 0.7981.49 ± 0.811
HDL-C7.07 ± 0.7373.41 ± 0.748
Triglycerides-9.05 ± 2.0919.36 ± 2.124
Non-HDL-C-32.59 ± 1.0721.19 ± 1.089
Non-HDL-C/HDL-C-34.31 ± 1.288-0.38 ± 1.308
Statistical analysis
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -39.51 · 95% CI -43.08 to -35.94Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -25.46 · 95% CI -27.70 to -23.23Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: 3.67 · 95% CI 1.60 to 5.73Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -18.41 · 95% CI -24.26 to -12.55Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -33.78 · 95% CI -36.78 to -30.78Treatment as a fixed effect and baseline value as a covariate.
  • Rosuvastatin 20 mg vs Placebo · ANCOVA · p = <0.001 · Least squares mean difference: -33.93 · 95% CI -37.54 to -30.32Treatment as a fixed effect and baseline value as a covariate.

Adverse events

Collected over Treatment Emergent Adverse Events were collected from day of first dose in Week 0 up to and including 10 days following the date of last dose of investigational product or placebo (up to Week 104).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin 20 mg0/272 (0%)38/272 (14%)144/272 (52.9%)
Placebo1/268 (0.4%)34/268 (12.7%)142/268 (53%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventRosuvastatin 20 mgPlacebo
Acute myocardial infarctionCardiac disorders0/2722/268
Arteriosclerosis coronary arteryCardiac disorders1/2722/268
Lumbar vertebral fractureInjury, poisoning and procedural complications0/2722/268
OsteoarthritisMusculoskeletal and connective tissue disorders1/2722/268
CataractEye disorders2/2721/268
Spinal osteoarthritisMusculoskeletal and connective tissue disorders2/2720/268
Cerebral infarctionNervous system disorders2/2720/268
Angina unstableCardiac disorders0/2721/268
ArrhythmiaCardiac disorders1/2721/268
Coronary artery diseaseCardiac disorders0/2721/268
Most frequent other events
Most frequent other events
EventRosuvastatin 20 mgPlacebo
NasopharyngitisInfections and infestations52/27256/268
Upper respiratory tract infectionInfections and infestations49/27254/268
Blood glucose increasedInvestigations24/27218/268
ToothacheGastrointestinal disorders23/27215/268
HypertensionVascular disorders19/27221/268
DizzinessNervous system disorders14/27216/268
Protein urine presentInvestigations16/2729/268
CoughRespiratory, thoracic and mediastinal disorders14/27215/268

Baseline characteristics

The intent-to-treat (ITT) analysis set consisted of all randomized patients.

Age, Continuous
Age, Continuous(years)Rosuvastatin 20 mgPlaceboTotal
Mean59.0 ± 5.2359.7 ± 4.9659.4 ± 5.11
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin 20 mgPlaceboTotal
Female146158304
Male126113239
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rosuvastatin 20 mgPlaceboTotal
Asian272271543
10-year ICVD Risk
10-year ICVD Risk(Participants)Rosuvastatin 20 mgPlaceboTotal
<5%196195391
≥5% - <10%7676152
08

Study locations

24 sites
  • Research Site
    Beijing, 100035, China
  • Research Site
    Beijing, 100050, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100853, China
  • Research Site
    Bengbu, 233060, China
  • Research Site
    Changsha, 410011, China
  • Research Site
    Chongqin, 400042, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, 510260, China
  • Research Site
    Guangzhou, 510515, China
  • Research Site
    Guangzhou, 510630, China
  • Research Site
    Haerbin, 150001, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Ningbo, 315010, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, 200065, China
  • Research Site
    Shanghai, 200090, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300457, China
  • Research Site
    Wenzhou, CN-325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xian, 710061, China
09

References and documents

Publications

  • Zheng H, Li H, Wang Y, Li Z, Hu B, Li X, Fu L, Hu H, Nie Z, Zhao B, Wei D, Karlson BW, Bots ML, Meng X, Chen Y, Wang Y; METEOR-China Investigators. Rosuvastatin Slows Progression of Carotid Intima-Media Thickness: The METEOR-China Randomized Controlled Study. Stroke. 2022 Oct;53(10):3004-3013. doi: 10.1161/STROKEAHA.120.031877. Epub 2022 Aug 26. PubMed 36017704 ↗
  • Wang Y, Wang A, Li H, Li Z, Hu B, Li X, Zheng H, Fu L, Hu H, Nie Z, Qin Y, Zhao B, Wei D, Karlson BW, Bots ML, Chen Y, Wang Y. Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study. Trials. 2020 Nov 11;21(1):921. doi: 10.1186/s13063-020-04741-0. PubMed 33176842 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Jan 2019, 40 months.

Results were first posted in Dec 2019, 10 months after primary completion.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's 40 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2015
First posted
Sep 10, 2015
StartActual
Sep 17, 2015
Primary completionActual
Jan 29, 2019
CompletionActual
Jan 29, 2019
Results first posted
Dec 11, 2019
Last update
Dec 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02546323
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 10, 2015
Start date
Sep 17, 2015
Primary completion
Jan 29, 2019
Completion
Jan 29, 2019
Results posted
Dec 11, 2019
Last update
Dec 11, 2019

Study contacts

Yongjun Wang, M.D.
principal investigator · Beijing Tian Tan Hospital, Capital Medical University
Yundai Chen, M.D.
principal investigator · Chinese PLA General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion